Therascope AG, a privately held biopharmaceutical company focused on small molecule drug discovery utilizing its unique TACE synthesis and screening technology, today announced the completion of a € 24.1 million (approximately $ 27.7 million) second round of institutional preferred stock financing. The round was led by Oxford Bioscience Partners in Boston. Earlybird Venture Capital in Hamburg acted as local co-lead for the round. Subsequent to the closing Matthias Jaffé, a principal at Earlybird, joined Therascope as Vice President of Finance.

For further information please see attached press release or contact:

Rolf Mathies
EARLYBIRD
Van-der-Smissen-Str. 3
22767 Hamburg
Germany
Tel.: +49 (40) 43 29 41-0
Fax: +49 (40) 43 29 41-29
mathies@earlybird.com

    030718 Therascope_Alantos_FINAL.pdf